4-IPP (4-Iodo-6-phenylpyrimidine) 是巨噬细胞迁移抑制因子 (MIF) 的特异性自杀底物和不可逆抑制剂。
| 生物活性 | 4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor ofmacrophage migration inhibitory factor (MIF)[1]. |
| IC50& Target | |
体外研究
(In Vitro) | 4-IPP is a specific suicide substrate for MIF that binds covalently and irreversibly to MIF to inhibit its biologic activity[1].
4-IPP inhibits RANKL-induced p65 phosphorylation and nuclear translocation by preventing the interaction of MIF with thioredoxin-interacting protein-p65 complexes[1].
4-IPP can inhibit receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and potentiate osteoblast-mediated mineralization and bone nodule formation[1].
4-IPP (0.5-200μM;24-72 hours) inhibits osteoclastogenesis in a dose-dependent manner[1].
4-IPP(5-20μM; 5 days) inhibits RANKL-induced osteoclast differentiation and bone resorption[1].
Cell Cytotoxicity Assay[1] | Cell Line: | BMMs | | Concentration: | 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 25 μM, 50 μM, 100 μM, 200 μM | | Incubation Time: | 24 hours, 72 hours | | Result: | Inhibited osteoclastogenesis in a dose-dependent manner. |
Western Blot Analysis[1] | Cell Line: | BMMs | | Concentration: | 5 μM,10 μM, 20 μM | | Incubation Time: | 1 day, 3 days, 5 days | | Result: | Inhibited RANKL-induced osteoclast differentiation and bone resorption. |
|
体内研究
(In Vivo) | 4-IPP (1 mg/kg, 5 mg/kg; every 2 days; for 8 weeks) ameliorates the bone loss associated with estrogen deficiency by reducing osteoclastic activities and enhancing osteoblastic bone formation[1].
| Animal Model: | 8-weeks-old C57BL/6J male mice[1] | | Dosage: | 1 mg/kg, 5 mg/kg | | Administration: | Intraperitoneal injection; every 2 days; for 8 weeks | | Result: | Alleviated OVX-induced osteoporosis. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: DMSO : 250 mg/mL(886.27 mM;Need ultrasonic) 配制储备液 | 1 mM | 3.5451 mL | 17.7255 mL | 35.4509 mL | | 5 mM | 0.7090 mL | 3.5451 mL | 7.0902 mL | | 10 mM | 0.3545 mL | 1.7725 mL | 3.5451 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 6.25 mg/mL (22.16 mM); Clear solution
此方案可获得 ≥ 6.25 mg/mL (22.16 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 62.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂： 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 6.25 mg/mL (22.16 mM); Clear solution
此方案可获得 ≥ 6.25 mg/mL (22.16 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 62.5 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。 3. 请依序添加每种溶剂： 10% DMSO 90%corn oil Solubility: ≥ 6.25 mg/mL (22.16 mM); Clear solution
此方案可获得 ≥ 6.25 mg/mL (22.16 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例，取 100 μL 62.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。 *以上所有助溶剂都可在本网站选购。
|
m.cnreagent.com